KPV vs TB-500 (Thymosin Beta-4)
Updated July 21, 2026 · Reviewed by the PeptidesDB Editorial team
A data-driven comparison of KPV and TB-500 (Thymosin Beta-4) (also searched as TB-500 (Thymosin Beta-4) vs KPV) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.
Verdict
KPV centers on healing, while TB-500 (Thymosin Beta-4) leans toward healing. On indexed research, KPV is ahead (KPV: 6 studies, Human evidence; TB-500 (Thymosin Beta-4): 3, Preclinical). Choose by goal — and read the primary studies. This is research information, not medical advice.
Key takeaways
- •KPV is strongest for healing; TB-500 (Thymosin Beta-4) for healing.
- •Evidence: KPV Human evidence (6 studies) vs TB-500 (Thymosin Beta-4) Preclinical (3).
- •Both are research-use compounds — not FDA-approved.
Effect profiles, overlaid
At a glance
Anti-Inflammatory Tripeptide | Alpha-MSH Fragment
KPV vs TB-500 (Thymosin Beta-4): side-by-side
| Metric | KPV | TB-500 (Thymosin Beta-4) |
|---|---|---|
| Class | Immune | — |
| Regulatory status | Research use only | Research use only |
| Evidence grade | Human evidence | Preclinical |
| Studies indexed | 6 | 3 |
| Research level | Emerging | — |
| Strongest effect | Healing & recovery | Healing & recovery |
| Healing & recovery | 4.0▲ | 4.0▲ |
| Muscle & body comp | 0.0 | 3.0▲ |
| Metabolic & appetite | 0.0 | 2.0▲ |
| Neuro & mood | 0.0 | 1.0▲ |
| Sleep & circadian | 0.0 | 1.0▲ |
| Inflammation & immune | 4.0▲ | 4.0▲ |
| Skin & aesthetics | 2.0▲ | 2.0▲ |
▲ marks the higher community effect score (0–5 perceived-effect signal, not clinical efficacy).
Mechanism & pharmacokinetics
| Property | KPV | TB-500 (Thymosin Beta-4) |
|---|---|---|
| Mechanism | — | Actin-sequestering peptide; promotes cell migration & angiogenesis |
| Route | — | Subcutaneous injection (research use) |
Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.
What is KPV?
### KPV Summary KPV is a tripeptide composed of lysine, proline, and valine, which has garnered interest in research for its potential roles in modulating immune responses and promoting wound healing. Its implications in various therapeutic contexts, particularly in inflammatory conditions, are currently being explored.
Full KPV profile, mechanism & studies →What is TB-500 (Thymosin Beta-4)?
### Summary TB-500, a synthetic derivative of thymosin beta-4, is a peptide that has garnered attention for its potential role in tissue repair and regeneration. Research into TB-500 is ongoing, particularly regarding its applications in equine medicine and its implications in doping control.
Full TB-500 (Thymosin Beta-4) profile, mechanism & studies →Which is better for your goal?
| Goal | Better fit | Why |
|---|---|---|
| Healing | Even | Both ~4.0/5 |
| Muscle | TB-500 (Thymosin Beta-4) | 3.0/5 effect signal |
| Metabolic | TB-500 (Thymosin Beta-4) | 2.0/5 effect signal |
| Neuro | TB-500 (Thymosin Beta-4) | 1.0/5 effect signal |
| Sleep | TB-500 (Thymosin Beta-4) | 1.0/5 effect signal |
| Inflammation | Even | Both ~4.0/5 |
| Skin | Even | Both ~2.0/5 |
Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.
Can you stack KPV and TB-500 (Thymosin Beta-4)?
People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because neither compound is FDA-approved, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.
KPV vs TB-500 (Thymosin Beta-4): side effects
No community-reported effects logged yet.
No community-reported effects logged yet.
Anonymous community reports (count = number of reports), not clinical incidence rates.
What the research says
KPV has 6 approved studies indexed (Human evidence), and TB-500 (Thymosin Beta-4) has 3 (Preclinical). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.
Frequently asked questions
Is KPV or TB-500 (Thymosin Beta-4) better?
It depends on your goal. KPV is strongest for healing; TB-500 (Thymosin Beta-4) for healing. KPV has more indexed studies (6). See the goal-by-goal breakdown above.
Is KPV or TB-500 (Thymosin Beta-4) better for weight loss?
TB-500 (Thymosin Beta-4) shows the stronger metabolic & appetite profile (2.0/5) in community effect data — though weight-loss outcomes depend on the individual and the evidence base.
Is KPV or TB-500 (Thymosin Beta-4) better for muscle?
TB-500 (Thymosin Beta-4) leads on the muscle & body-composition axis (3.0/5).
Which has more research, KPV or TB-500 (Thymosin Beta-4)?
KPV has 6 approved studies indexed (Human evidence); TB-500 (Thymosin Beta-4) has 3 (Preclinical). Higher counts mean more to read, not proven superiority.
Can you stack KPV and TB-500 (Thymosin Beta-4)?
Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.
What are the side effects of KPV vs TB-500 (Thymosin Beta-4)?
KPV: no community-reported effects logged yet. TB-500 (Thymosin Beta-4): none logged yet. These are anonymous reports, not incidence rates — see each profile.
Is KPV or TB-500 (Thymosin Beta-4) FDA-approved?
KPV is a research-use compound and is not FDA-approved. TB-500 (Thymosin Beta-4) is not FDA-approved. Research-use status is not a legal clearance to compound or use in humans.
Is TB-500 (Thymosin Beta-4) better than KPV?
For healing, TB-500 (Thymosin Beta-4) has the edge; for healing, KPV does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.
Comparing related peptides
Regulatory & legal status
KPV and TB-500 (Thymosin Beta-4) are research-use compounds and are not FDA-approved for human use. FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed July 21, 2026.